Chicago Equity Partners LLC Grows Holdings in Chemed Corp. (CHE)
Chicago Equity Partners LLC grew its position in Chemed Corp. (NYSE:CHE) by 80.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,595 shares of the company’s stock after acquiring an additional 14,065 shares during the quarter. Chicago Equity Partners LLC owned 0.20% of Chemed Corp. worth $6,384,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC bought a new position in shares of Chemed Corp. during the 2nd quarter valued at approximately $120,000. Pacad Investment Ltd. increased its position in shares of Chemed Corp. by 250.0% during the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after purchasing an additional 500 shares during the last quarter. IFP Advisors Inc increased its position in shares of Chemed Corp. by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after purchasing an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Chemed Corp. by 12.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after purchasing an additional 83 shares during the last quarter. Finally, MCF Advisors LLC bought a new position in shares of Chemed Corp. during the 3rd quarter valued at approximately $152,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.
Shares of Chemed Corp. (NYSE CHE) opened at $232.36 on Wednesday. Chemed Corp. has a 1-year low of $134.52 and a 1-year high of $235.96. The firm has a market capitalization of $3,698.52, a price-to-earnings ratio of 28.53, a price-to-earnings-growth ratio of 4.90 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings data on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $2.00 by $0.15. The firm had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.73 EPS. sell-side analysts predict that Chemed Corp. will post 4.73 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Investors of record on Monday, November 13th will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Friday, November 10th. Chemed Corp.’s dividend payout ratio (DPR) is currently 24.89%.
In related news, Director Patrick P. Grace sold 500 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $201.48, for a total transaction of $100,740.00. Following the completion of the sale, the director now directly owns 4,515 shares in the company, valued at approximately $909,682.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin J. Mcnamara sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total value of $2,234,200.00. Following the sale, the chief executive officer now owns 170,016 shares of the company’s stock, valued at $37,984,974.72. The disclosure for this sale can be found here. Insiders have sold a total of 13,750 shares of company stock valued at $3,041,293 over the last 90 days. 4.90% of the stock is currently owned by company insiders.
WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/08/chicago-equity-partners-llc-grows-holdings-in-chemed-corp-che.html.
Several equities analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. boosted their target price on Chemed Corp. from $220.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Zacks Investment Research downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, September 13th. BidaskClub downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Royal Bank Of Canada reaffirmed a “hold” rating and issued a $209.00 price objective on shares of Chemed Corp. in a research report on Monday, July 31st. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Chemed Corp. currently has an average rating of “Hold” and a consensus target price of $236.00.
Chemed Corp. Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).
Receive News & Stock Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related stocks with our FREE daily email newsletter.